Euroz Hartleys Report | 25 October 2021

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.

Click here to view the report.

Euroz Hartleys Report | 29 September 2021

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.

Click here to view the report.

4th International Cannabinoid Derived Pharmaceuticals Summit

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

Research Report by Euroz Hartleys

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has initiated coverage on Botanix as we lead into an exciting 12 months of clinical studies and corporate activities.

This report reinforces our belief that Botanix has assembled the right people, technology and research strategies to advance our assets, and to deliver positive results for our shareholders and the patients we exist to serve.

Read the full report.

Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.

Click here to view the report.

Boston Herald AMR op-ed

Co-founder, president and CEO of Venatorx Pharmaceuticals, Christopher J. Burns PhD, and co-founder and CEO of Spero Therapeutics, Ankit Mahadevia, have joined forces to publish a powerful opinion editorial in the Boston Herald.

Their article, ‘Pasteur Act can reinvigorate broken antibiotic market’, investigates how this legislation can work to prevent over-subscribing of antibiotics and incentivised development of novel antibiotics, during an escalating global public health crisis caused by drug-resistant infection.

A brief excerpt:

‘Researchers warn that without new antibiotics, drug-resistant infections could kill 10 million people annually by 2050. Currently, they kill 700,000 per year, worldwide, and contribute to an additional $4.6 billion in increased health care costs per year in the United States alone.’

It highlights the importance of continued R&D in this space – something Botanix is proud to be prioritising with our BTX 1801 development program.

Read the full article here.

ABC News | Mask rules leads to rise in skin conditions

Skin specialists have reported an increase in people seeking treatment for skin conditions as a result of mandatory mask wearing in Australia due to COVID-19. 

Dubbed  ‘maskne’, the condition includes acne, rosacea flare ups, perioral dermatitis, and folliculitis, all of which are aggravated by substances such as oil, bacteria, and dead skin cells becoming trapped under the mask.

Read the full article on the ABC website here.

Investor Conference Call

Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021.

You may listen to the audio file here:

Ticker News Interview

Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.

Investor Presentation + Conference Call

Botanix Pharmaceuticals has today released an updated investor presentation and registration details for a conference call with our investors and supporters.

participants can pre-submit questions to be answered at the end of the call, when registering through the link below.

See the updated investor presentation here.

Conference call details:

Date: Friday, 7 May 2021

Time: 11:00am AEST

Registration details:

Participants are encouraged to pre-register for the conference call. Upon registration, participants will receive a unique pin granting fast-track access to the conference call and the opportunity to submit questions to our team.

Register now.